ASND - CIK 0001612042
Ascendis Pharma A/S trades as ASND and has a market capitalization of $13.00 B, making it the #797 largest US-listed company by market value. This page tracks Ascendis Pharma A/S through 763 SEC filings, with financial statements and metrics updated as new reports are filed.
| Filing | Type | Filed |
|---|---|---|
| SD | - | 2026-05-22 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-14 |
| 6-K | - | 2026-05-13 |
| Insider trade | 4 | 2026-05-12 |
| Insider sale notice | 144 | 2026-05-11 |
| SCHEDULE 13G/A | - | 2026-05-07 |
| SCHEDULE 13G | - | 2026-05-07 |
Those who would like to participate may access the live webcast here , or register in advance for the teleconference here . The link to the live webcast will also be available on the Investors & News section of the Ascendis Pharma website at https://investors.ascendispharma.com . A replay of the webcast will be available on this section of the Ascendis Pharma website shortly after the conclusion of the event for 30 days.
Ascendis Pharma Reports First Quarter 2026 Financial Results | Ascendis Pharma
New 2-Year Data from Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) Show Pronounced Gains in Growth Outcomes in Children with Achondroplasia Aged ≥5 Years | Ascendis Pharma
Ascendis Announces Redemption of All $575 Million of Outstanding 2.25% Convertible Senior Notes Due 2028 | Ascendis Pharma
The largest companies sharing Ascendis Pharma A/S's SEC industry classification (pharmaceutical preparations).
Ascendis Pharma A/S (ASND) has a market capitalization of $13.00 B as of 2026-06-10, ranking #797 among US-listed companies.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Ascendis Pharma Announces Commencement of Trading of its Ordinary Shares on Nasdaq | Ascendis Pharma